IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.416
NA - Nord America 6.830
AS - Asia 4.907
SA - Sud America 755
Continente sconosciuto - Info sul continente non disponibili 531
AF - Africa 91
OC - Oceania 9
Totale 22.539
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 6.861
US - Stati Uniti d'America 6.628
SG - Singapore 1.764
CN - Cina 1.000
IT - Italia 814
VN - Vietnam 776
IE - Irlanda 774
HK - Hong Kong 686
BR - Brasile 625
GB - Regno Unito 256
DE - Germania 222
KR - Corea 211
IN - India 185
FR - Francia 104
CA - Canada 93
UA - Ucraina 60
AR - Argentina 55
GR - Grecia 54
BD - Bangladesh 53
JP - Giappone 49
AT - Austria 48
FI - Finlandia 44
MX - Messico 42
SE - Svezia 41
NL - Olanda 29
CO - Colombia 28
ID - Indonesia 28
TR - Turchia 25
IQ - Iraq 23
BE - Belgio 22
MA - Marocco 21
ES - Italia 18
EG - Egitto 17
PK - Pakistan 17
ZA - Sudafrica 17
PL - Polonia 14
CR - Costa Rica 13
KE - Kenya 13
HN - Honduras 11
LT - Lituania 11
SA - Arabia Saudita 11
UZ - Uzbekistan 11
VE - Venezuela 11
EC - Ecuador 10
JM - Giamaica 10
CL - Cile 8
PR - Porto Rico 7
TN - Tunisia 7
AU - Australia 6
EE - Estonia 6
IL - Israele 6
JO - Giordania 6
MY - Malesia 6
AE - Emirati Arabi Uniti 5
GT - Guatemala 5
NI - Nicaragua 5
NP - Nepal 5
PE - Perù 5
PY - Paraguay 5
TH - Thailandia 5
TW - Taiwan 5
UY - Uruguay 5
CH - Svizzera 4
CZ - Repubblica Ceca 4
KZ - Kazakistan 4
NO - Norvegia 4
PH - Filippine 4
RS - Serbia 4
EU - Europa 3
IR - Iran 3
LB - Libano 3
MD - Moldavia 3
RO - Romania 3
SC - Seychelles 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
BW - Botswana 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GY - Guiana 2
KH - Cambogia 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
AG - Antigua e Barbuda 1
AN - Antille olandesi 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
Totale 21.988
Salva come PNG Salva come JPEG
Città #
Moscow 2.579
San Jose 1.151
Singapore 776
Dublin 760
Santa Clara 730
Hong Kong 671
Ashburn 611
Council Bluffs 457
Chandler 359
Ho Chi Minh City 261
Hefei 246
Seoul 203
Hanoi 181
New York 146
Beijing 144
Milan 127
Princeton 112
Dallas 109
The Dalles 102
Jacksonville 101
Roxbury 94
Los Angeles 91
Bengaluru 90
Naples 86
São Paulo 57
Da Nang 55
Nuremberg 53
Cambridge 49
North Bergen 49
Medford 48
Bremen 44
Atlanta 42
Rome 38
Miano 36
Falkenstein 35
San Francisco 35
Phoenix 33
Boardman 32
Des Moines 32
Haiphong 30
Ann Arbor 26
Caserta 26
Orem 26
Denver 25
Kochi 25
Wilmington 24
Brooklyn 23
Brussels 22
Montreal 22
Aversa 21
Tokyo 21
Rio de Janeiro 20
Chicago 19
Frankfurt am Main 19
Toronto 19
Brasília 18
Hyderabad 18
Lappeenranta 18
Houston 17
Thái Nguyên 17
Biên Hòa 16
Helsinki 16
Mexico City 16
Munich 16
Boston 15
Nanjing 15
Vienna 15
Amsterdam 14
Belo Horizonte 14
Dhaka 14
Memphis 14
London 13
Bologna 12
Hải Dương 12
Bến Tre 11
Chennai 11
Guangzhou 11
Nairobi 11
Nha Trang 11
Ninh Bình 11
Tashkent 11
Campinas 10
Curitiba 10
Ercolano 10
Hangzhou 10
Johannesburg 10
Napoli 10
Porto Alegre 10
Salvador 10
San José 10
Shenzhen 10
Turin 10
Bari 9
Bogotá 9
Cairo 9
Columbus 9
Jinan 9
Thái Bình 9
Buffalo 8
Florence 8
Totale 11.740
Salva come PNG Salva come JPEG
Nome #
Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis 599
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 282
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 275
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 270
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 229
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 192
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 186
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 184
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 176
Natural history of left ventricular hypertrophy in infants of diabetic mothers 175
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 173
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 172
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 171
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 163
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 162
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 160
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 160
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 158
[The COMPASS study] 156
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 153
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 153
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 150
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 149
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 146
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 146
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 146
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 145
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 145
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 142
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 142
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 141
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 140
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 139
A call for action in bleeding prevention 138
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 137
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 136
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 135
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 135
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 134
[Debate on antiplatelet monotherapy: P2Y12 inhibitor monotherapy in patients with coronary artery disease] 133
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 133
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 132
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 132
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 131
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 130
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 125
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 125
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy? 124
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 123
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 123
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 123
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 122
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 120
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 120
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 119
Echocardiographic monitoring in cancer therapy: clinical guidance for cardiologists and oncologists 118
Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions 118
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 118
A pragmatic approach for thrombotic prevention after acute coronary syndromes 117
Are we ready for a gender-specific approach in interventional cardiology? 117
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 116
Early-onset MINOCA: Prognostic implications and considerations for practice 116
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 114
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 114
Inflammation in patients undergoing transcatheter aortic valve implantation: a therapeutic target for the future? 113
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis 113
Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) 113
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 113
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 113
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 113
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 111
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 111
De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials 111
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 111
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 111
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 110
The year in cardiovascular pharmacotherapy 2022: landmark evidence at a glance 109
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 109
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 109
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 108
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 108
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 108
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 108
Severely calcified coronary artery lesions: focus on interventional management 107
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 107
OCEANIC-AF trial: factor XI inhibitors revolution in atrial fibrillation is on hold 106
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 106
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 106
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience 105
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 105
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 104
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 104
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 104
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 103
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 103
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 103
P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions 102
SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection 101
Pathophysiology and Treatment of the No-Reflow Phenomenon in ST-Segment Elevation Myocardial Infarction: Focus on Low-Dose Fibrinolysis during Primary Percutaneous Intervention 101
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 101
Totale 13.828
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022759 0 0 0 28 194 11 12 121 21 93 59 220
2022/20231.332 129 73 32 93 121 72 4 69 672 8 26 33
2023/2024734 44 21 22 37 191 108 54 6 6 33 54 158
2024/20252.890 7 28 8 77 452 383 357 237 403 463 280 195
2025/202612.700 458 679 657 584 947 6.404 914 883 462 400 192 120
2026/20273.451 574 753 1.058 1.066 0 0 0 0 0 0 0 0
Totale 22.539